Induction of Neutrophilic Traps ( NETs ) by the Environment and Infectious Inflammatory Lung Cystic Fibrosis (MucoNETs)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02564393|
Recruitment Status : Completed
First Posted : September 30, 2015
Last Update Posted : September 30, 2015
The study is defined in 3 stages of in vitro assays :
Phase 1 : Secretion of NETs in response to lung disease and their secretion of factors.
This is a transversal study in which we compare :
- Producing NETs (DNA and proteases ) by neutrophils purified from sputum and blood of patients
- Producing NETs (DNA and proteases ) by purified neutrophils in the blood of patients and blood of control subjects
Phase 2: Mechanisms of activation of NETs secretory pathways . This phase will identify receptors (TLR ) involved in the secretion of NETs and analyze the involvement of dependent transduction pathways calcium and PKC . It will be performed on control blood neutrophils.
Phase 3: Analysis of cell death ( NETose )
This is a transversal study that will analyze :
the mode of cell death of neutrophils purified blood and sputum of patients and control blood neutrophils by flow cytometry and transmission electron microscopy .
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||55 participants|
|Observational Model:||Case Control|
|Official Title:||Secretion Induction of Neutrophil Extracellular Traps (NETs)in Inflammatory and Infectious Environment of Mucoviscidose|
|Study Start Date :||May 2011|
|Actual Primary Completion Date :||May 2013|
Adult with cystic fibrosis
- the DNA concentration secreted into the extracellular environment neutrophil activated [ Time Frame: 1 hour ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02564393
|CHRU de Tours|